Huang Huang

Huang Huang

Auto-generated profile, based on publicly available information

Huang Huang

Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, 130 Mei Long Road, Shanghai 200237, China

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2019 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
SKSzymon Klossowski
Szymon Klossowski
HMHongzhi Miao
Hongzhi Miao
KKKatarzyna Kempinska
Katarzyna Kempinska
TWTao Wu
Tao Wu
TPTrupta Purohit
Trupta Purohit
JGJolanta Grembecka
Jolanta Grembecka
The protein-protein interaction between menin and Mixed Lineage Leukemia 1 (MLL1) plays a critical role in acute leukemias with translocations of the MLL1 gene or with mutations in the Nucleophosmin 1 (NPM1) gene. As a step toward clinical translation of menin-MLL1 inhibitors, we report development of MI-3454, a highly potent and orally bioavailable inhibitor of the menin-MLL1 interaction. MI-3454 profoundly inhibited proliferation and induced differentiation in acute leukemia cells and primary patient samples with MLL1 translocations or NPM1 mutations. When applied as a single agent, MI-3454 induced complete remission or regression of leukemia in mouse models of MLL1-rearranged or NPM1-mutated leukemia, including patient-derived xenograft models, through downregulation of key genes involved in leukemogenesis. We also identified MEIS1 as a potential pharmacodynamic biomarker of treatment response with MI-3454 in leukemia, and demonstrated that this compound is well tolerated and did not impair normal hematopoiesis in mice. Overall, this study demonstrates for the first time profound activity of the menin-MLL1 inhibitor as a single agent in clinically relevant PDX models of leukemia. These data provide a strong rationale for clinical translation of MI-3454 or its analogs for leukemia patients with MLL1-rearrangements or NPM1 mutations

31 August 2020 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
HHHuang Huang
Huang Huang
CHChristina A. Howard
Christina A. Howard
SZSergei Zari
Sergei Zari
HCHyo Je Cho
Hyo Je Cho
SSShirish Shukla
Shirish Shukla
TCTomasz Cierpicki
Tomasz Cierpicki

3 August 2012 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
HHHuang Huang
Huang Huang
YYYing Yu
Ying Yu
ZGZhenting Gao
Zhenting Gao
YZYong Zhang
Yong Zhang
CLChenjing Li
Chenjing Li
JLJian Li
Jian Li

7 June 2011 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JDJing Deng
Jing Deng
EFEnguang Feng
Enguang Feng
SMSheng Ma
Sheng Ma
YZYan Zhang
Yan Zhang
XLXiaofeng Liu
Xiaofeng Liu
JLJian Li
Jian Li

1 January 2012 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
HHHuang Huang
Huang Huang
WLweiqiang lu
weiqiang lu
XLXi Li
Xi Li
XCXiaoli Cong
Xiaoli Cong
HMHongmei Ma
Hongmei Ma
JZJin Zhu
Jin Zhu

27 May 2023 in Expert Opinion on Drug Discovery
Verified
Journal Article
Closed access
HHHuang Huang
Huang Huang
LJLyn H. Jones
Lyn H. Jones
Covalent drug discovery has traditionally focused on targeting cysteine, but the amino acid is often absent in protein binding sites. This review makes the case to move beyond cysteine labeling using sulfur (VI) fluoride exchange (SuFEx) chemistry to expand the druggable proteome. Recent advances in SuFEx medicinal chemistry and chemical biology are described, which have enabled the development of covalent chemical probes that site-selectively engage amino acid residues (including tyrosine, lysine, histidine, serine, and threonine) in binding pockets. Areas covered include chemoproteomic mapping of the targetable proteome, structure-based design of covalent inhibitors and molecular glues, metabolic stability profiling, and synthetic methodologies that have expedited the delivery of SuFEx modulators. Despite recent innovations in SuFEx medicinal chemistry, focused preclinical research is required to ensure the field moves from early chemical probe discovery to the delivery of transformational covalent drug candidates. The authors believe that covalent drug candidates designed to engage residues beyond cysteine using sulfonyl exchange warheads will likely enter clinical trials in the coming years.